Cholesteryl ester transfer protein polymorphisms, statin use, and their impact on cholesterol levels and cardiovascular events

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 3, 2014, Pages 314-320

  Leusink, M ^a,b   Onland Moret, N C ^b   Asselbergs, F W ^b   Ding, B ^c   Kotti, S ^d   Van Zuydam, N R ^e   Papp, A C ^f   Danchin, N ^g,h   Donnelly, L ^e   Morris, A D ^e   Chasman, D I ^i,j   Doevendans, P A F M ^b   Klungel, O H ^a   Ridker, P M ^i,j   Van Gilst, W H ^k   Simon, T ^d,l   Nyberg, F ^c,m   Palmer, C N A ^e   Sadee, W ^f   Van Der Harst, P ^k   De Bakker, P I W ^b,j   De Boer, A ^a   Verstuyft, C ^n,o   Maitland Van Der Zee, A H ^a   more..

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ASTRAZENECA R AND D   (Sweden)

^d HÔPITAL SAINT ANTOINE   (France)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^l SORBONNE UNIVERSITÉ   (France)

^m UNIVERSITY OF GOTHENBURG   (Sweden)

ⁿ BICÊTRE HOSPITAL   (France)

^o UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84894487302     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.194     Document Type: Article

References (29)

1. Nicholls, S.J. et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297, 499-508 (2007).
2. Cheung, B.M., Lauder, I.J., Lau, C.P. & Kumana, C.R. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br. J. Clin. Pharmacol. 57, 640-651 (2004).
3. Chasman, D.I., Giulianini, F., MacFadyen, J., Barratt, B.J., Nyberg, F. & Ridker, P.M. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ. Cardiovasc. Genet. 5, 257-264 (2012).
4. Thompson, G.R., O'Neill, F. & Seed, M. Why some patients respond poorly to statins and how this might be remedied. Eur. Heart J. 23, 200-206 (2002).
5. Brown, M.L. et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 342, 448-451 (1989).
6. Teslovich, T.M. et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707-713 (2010).
7. Boekholdt, S.M. et al. Cholesteryl ester transfer protein TaqIB variant, highdensity lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 111, 278-287 (2005).
8. Ridker, P.M., Paré, G., Parker, A.N., Zee, R.Y., Miletich, J.P. & Chasman, D.I. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ. Cardiovasc. Genet. 2, 26-33 (2009).
9. Kuivenhoven, J.A. et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N. Engl. J. Med. 338, 86-93 (1998).
10. Kark, J.D., Sinnreich, R., Leitersdorf, E., Friedlander, Y., Shpitzen, S. & Luc, G. Taq1B CETP polymorphism, plasma CETP, lipoproteins, apolipoproteins and sex differences in a Jewish population sample characterized by low HDLcholesterol. Atherosclerosis 151, 509-518 (2000).
11. Papp, A.C. et al. Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS ONE 7, e31930 (2012).
12. Inazu, A. et al. Alternative splicing of the mRNA encoding the human cholesteryl ester transfer protein. Biochemistry 31, 2352-2358 (1992).
13. Lira, M.E., Loomis, A.K., Paciga, S.A., Lloyd, D.B. & Thompson, J.F. Expression of CETP and of splice variants induces the same level of ER stress despite secretion efficiency differences. J. Lipid Res. 49, 1955-1962 (2008).
14. CARDIoGRAMplusC4D Consortium et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat. Genet. 45, 25-33 (2013).
15. Willer, C.J. et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40, 161-169 (2008).
16. Veyrieras, J.B. et al. High-resolution mapping of expression-QTLs yields insight into human gene regulation. PLoS Genet. 4, e1000214 (2008).
17. Agerholm-Larsen, B., Nordestgaard, B.G., Steffensen, R., Jensen, G. & Tybjaerg-Hansen, A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 101, 1907-1912 (2000).
18. Voight, B.F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380, 572-580 (2012).
19. Barter, P.J. et al.; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007).
20. Lüscher, T.F. et al.; dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur. Heart J. 33, 857-865 (2012).
21. Roche. Roche provides update on Phase III study of dalcetrapib [media release] (2012). Accessed 30 August 2012.
22. Lange, R.A. & Lindsey, M.L. HDL-cholesterol levels and cardiovascular risk: acCETPing the context. Eur. Heart J. 29, 2708-2709 (2008).
23. Barter, P.J., Nicholls, S., Rye, K.A., Anantharamaiah, G.M., Navab, M. & Fogelman, A.M. Antiinflammatory properties of HDL. Circ. Res. 95, 764-772 (2004).
24. Van Lenten, B.J. et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96, 2758-2767 (1995).
25. von Eckardstein, A. Mulling over the odds of CETP inhibition. Eur. Heart J. 31, 390-393 (2010).
26. Guerin, M. et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 163, 287-296 (2002).
27. Team RDC. R: A Language and Environment for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0 (2011).
28. Higgins, J.P., Thompson, S.G., Deeks, J.J. & Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 327, 557-560 (2003).
29. Gauderman, W.J. Sample size requirements for association studies of genegene interaction. Am. J. Epidemiol. 155, 478-484 (2002).